Bcl-2

シグナル伝達経路

研究分野

阻害剤の選択性比較

カタログ番号	製品カタログ	溶解度(25°C)
カタログ番号	製品カタログ	水	DMSO	アルコール
S1002	ABT-737	<1 mg/mL	100 mg/mL	<1 mg/mL
S1001	Navitoclax (ABT-263)	<1 mg/mL	100 mg/mL	<1 mg/mL
S1121	TW-37	<1 mg/mL	115 mg/mL	4 mg/mL
S8048	Venetoclax (ABT-199, GDC-0199)	<1 mg/mL	100 mg/mL	<1 mg/mL
S8643	AZD5991	<1 mg/mL	100 mg/mL	<1 mg/mL
S8836	S64315 (MIK665)	<1 mg/mL	100 mg/mL	-1 mg/mL
S8759	S55746 (S 055746,BCL201)	<1 mg/mL	100 mg/mL	<1 mg/mL
S2812	AT101	<1 mg/mL	116 mg/mL	89 mg/mL
S8061	Sabutoclax	<1 mg/mL	100 mg/mL	54 mg/mL
S7790	A-1210477	<1 mg/mL	3 mg/mL	<1 mg/mL
S2448	Gambogic Acid	<1 mg/mL	100 mg/mL	100 mg/mL
S8383	S63845		100 mg/mL
S8177	BH3I-1	<1 mg/mL	64 mg/mL	13 mg/mL
S7800	A-1155463	<1 mg/mL	80 mg/mL	<1 mg/mL
S7801	A-1331852	<1 mg/mL	100 mg/mL	<1 mg/mL
S7531	UMI-77	<1 mg/mL	93 mg/mL	93 mg/mL
S7105	BAM7	<1 mg/mL	2 mg/mL	<1 mg/mL
S1057	Obatoclax Mesylate (GX15-070)	<1 mg/mL	83 mg/mL	<1 mg/mL
S7849	BDA-366	<1 mg/mL	84 mg/mL	5 mg/mL
S7126	Marinopyrrole A (Maritoclax)	<1 mg/mL	100 mg/mL	45 mg/mL
S8865	BAI1	<1 mg/mL	18 mg/mL	3 mg/mL
S8650	BTSA1	<1 mg/mL	81 mg/mL	<1 mg/mL

亜型選択性的な製品

Bcl-2製品

All (22) Bcl-2阻害剤(16) Bcl-2活性剤(1) Bcl-2拮抗剤(3) Bcl-2モジュレータ(2) 新Bcl-2製品

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1002	ABT-737 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.	Cancer Res, 2019, 79(9):2339-2351 Cell Rep, 2019, 27(12):3657-3671 Cell Rep, 2019, 27(3):820-834	Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.
S1001	Navitoclax (ABT-263) Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.	Cell, 2019, 178(2):302-315.e23 Cell, 2019, 178(2):361-373 Cancer Cell, 2019, 36(2):179-193
S1121	TW-37 TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.	Cancer Res, 2018, 78(16):4704-4715 PLoS One, 2018, 13(1):e0190682 Nature, 2017, 551(7679):247-250	(a) H23 cells exposed for 0–24 h to TW-37 (10 uM) with and without ZVAD.fmk (50 uM) were monitored for apoptotic morphology using electron microscopy (scale bar, 5 mm). % PS positive cells indicate the percentage of apoptotic cells, characterised by PS externalisation.
S8048	Venetoclax (ABT-199, GDC-0199) Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.	Cell, 2019, 178(2):302-315.e23 Cancer Cell, 2019, 10.1016/j.ccell.2019.08.005 Cancer Cell, 2019, 35(5):752-766	THP-1 cells were treated with cytarabine alone and in combination with ABT-199 for 8 h. Whole cell lysates were extracted and subjected to Western blotting, and probed with anti-γH2AX or -β-actin antibody. Densitometry for γH2AX expression was measured, normalized to β-actin, and graphed as fold change compared to the no drug control. The data are presented as mean ± standard error from at least 3 independent Western blots. * indicates p < 0.05.
S8643^新	AZD5991
S8836^新	S64315 (MIK665) S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1 with Ki value of 1.2 nM and has potential pro-apoptotic and antineoplastic activities.
S8759^新	S55746 (S 055746,BCL201) S55746 (S 055746,BCL201) is a novel, orally active BCL-2 specific inhibitor (Ki = 1.3 nM) with poor affinity for BCL-XL and no significant binding to MCL-1, BFL-1 (BCL2A1/A1). The selectivity of S55746 for BCL-2 versus BCL-XL ranges from ~70 to 400 folds.
S2812	AT101 AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.	Invest New Drugs, 2019, 10.1007/s10637-019-00827-y Front Pharmacol, 2018, 9:1269 Cell Death Dis, 2016, 7:e2177	(B and C) assessment of antimigration capacity in each group by transwell migration assay. Abbreviations: CDDP, cisplatin; DMSO, dimethyl sulfoxide.
S8061	Sabutoclax Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.	Cancer Res, 2018, 78(4):1097-1109 Cancer Lett, 2018, 423:47-59 Cell Death Differ, 2016, 23(10):1681-90	(e) Abs (490 nm) was measured by MTS assay in siControl or siPTBP1 treated PC3 cells with DMSO, 1000 nM ABT737, or 100 nM Sabutoclax for 48 h, showing no significant change in cell viability following siPTBP1 treatment in DMSO control, ABT737, or Sabutoclax treated cells. (f) PC3 cells transfected with siControl or a mixture of two siPTBP1 were treated with 1000 nM ABT737 or 100 nM Sabutoclax combined with various doses of docetaxel for 48 h and cell viability was assessed by MTS assay. The viability of cells with 1000 nM ABT737 or 100 nM Sabutoclax alone was set as 100%. All data are presented as mean±S.E.M., n=3. The statistical significance was determined by unpaired student t-test where P<0.05; P<0.01; **P<0.001.
S7790	A-1210477 A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.	Cancer Cell, 2019, 35(5):752-766 Blood Cancer J, 2019, 9(2):4 Oncogene, 2019, 38(1):47-59	U251 glioblastoma (F) or MeWo melanoma (G) cells were treated with selective BH-3 mimetics, GTPP or the combination of both for 24 h (U251) or 48 h (MeWo). Thereafter, cells were stained with annexin V and propidium iodide and analyzed by flow cytometry. Shown are representative flow plots.
S2448	Gambogic Acid Gambogic Acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-X_L, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 μM, respectively.
S8383	S63845 S63845 is a new, selective MCL-1 inhibitor with the Kd value of 0.19 nM and has no discernible binding to the other BCL-2 members, BCL-2 or BCL-XL.	Cell, 2019, 178(2):302-315.e23 Nat Commun, 2019, 10(1):1444 Cell Rep, 2019, 27(12):3657-3671
S8177	BH3I-1 BH3I-1 is a Bcl-X_L-BH3 domain interaction inhibitor with Ki of 2.4 μM (by fluorescence polarization ).It is a selective inhibitor of Bcl-2 family proteins.
S7800	A-1155463 A-1155463, a highly potent and selective BCL-XL inhibitor, shows picomolar binding affinity to BCL-XL, and >1000-fold weaker binding to BCL-2 and related proteins BCL-W(Ki=19 nM) and MCL-1(Ki>440 nM).	Haematologica, 2018, 10.3324/haematol.2018.204958 Oncogenesis, 2018, 7(9):74	Tumor growth rate (TGR) of tumors orthotopically implanted in rats on day 3, 7 and 10 compared to day 0. Rats were treated with doxorubicin, A-1155463 or a combination. Treatment with A-1155463 resulted in a significant decrease in TGR compared to control mice.
S7801	A-1331852 A-1331852 is a potent and selectiveBCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.	Cancer Cell, 2019, 35(5):752-766 Cell Death Dis, 2019, 10(7):521 Cell Death Dis, 2019, 10(5):342	Cells were treated with 0.5 μM A-1331852 and 1.5 nM VCR (RD), 0.5 nM VCR (RH30) for 72 h. Apoptosis was determined by analysis of DNA fragmentation of PI-stained nuclei using flow cytometry. Mean and SD of three independent experiments performed in triplicate are shown; **P < 0.01.
S7531	UMI-77 UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.	Cell Death Dis, 2019, 10(3):185 BMC Cancer, 2017, 17(1):449 Mol Cell Biochem, 2017, 10.1007/s11010-017-2997-x	U87 and A172 cells were treated with UMI-77 (8 μM) for 24h and further treated with TRAIL (30 ng/ml) for indicated period of time. Levels of apoptosis-associated proteins were analyzed by Western blot. GAPDH was used as a loading control.
S7105	BAM7 BAM 7 is a direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
S1057	Obatoclax Mesylate (GX15-070) Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.	Cancer Cell, 2019, 36(1):68-83 Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011 Prostate, 2019, 79(11):1347-1359	In vivo antitumor efﬁcacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.
S7849	BDA-366 BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity.
S7126	Marinopyrrole A (Maritoclax) Marinopyrrole A (Maritoclax) is a selective Mcl-1 antagonist. It binds to Mcl-1, but not Bcl-XL, and targets Mcl-1 for proteasomal degradation. Maritoclax disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM.	Leukemia, 2019, 33(2):319-332
S8865^新	BAI1
S8650	BTSA1 BTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1002	ABT-737 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.	Cancer Res, 2019, 79(9):2339-2351 Cell Rep, 2019, 27(12):3657-3671 Cell Rep, 2019, 27(3):820-834	Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.
S1001	Navitoclax (ABT-263) Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.	Cell, 2019, 178(2):302-315.e23 Cell, 2019, 178(2):361-373 Cancer Cell, 2019, 36(2):179-193
S1121	TW-37 TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.	Cancer Res, 2018, 78(16):4704-4715 PLoS One, 2018, 13(1):e0190682 Nature, 2017, 551(7679):247-250	(a) H23 cells exposed for 0–24 h to TW-37 (10 uM) with and without ZVAD.fmk (50 uM) were monitored for apoptotic morphology using electron microscopy (scale bar, 5 mm). % PS positive cells indicate the percentage of apoptotic cells, characterised by PS externalisation.
S8048	Venetoclax (ABT-199, GDC-0199) Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.	Cell, 2019, 178(2):302-315.e23 Cancer Cell, 2019, 10.1016/j.ccell.2019.08.005 Cancer Cell, 2019, 35(5):752-766	THP-1 cells were treated with cytarabine alone and in combination with ABT-199 for 8 h. Whole cell lysates were extracted and subjected to Western blotting, and probed with anti-γH2AX or -β-actin antibody. Densitometry for γH2AX expression was measured, normalized to β-actin, and graphed as fold change compared to the no drug control. The data are presented as mean ± standard error from at least 3 independent Western blots. * indicates p < 0.05.
S8643^新	AZD5991
S8836^新	S64315 (MIK665) S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1 with Ki value of 1.2 nM and has potential pro-apoptotic and antineoplastic activities.
S8759^新	S55746 (S 055746,BCL201) S55746 (S 055746,BCL201) is a novel, orally active BCL-2 specific inhibitor (Ki = 1.3 nM) with poor affinity for BCL-XL and no significant binding to MCL-1, BFL-1 (BCL2A1/A1). The selectivity of S55746 for BCL-2 versus BCL-XL ranges from ~70 to 400 folds.
S2812	AT101 AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.	Invest New Drugs, 2019, 10.1007/s10637-019-00827-y Front Pharmacol, 2018, 9:1269 Cell Death Dis, 2016, 7:e2177	(B and C) assessment of antimigration capacity in each group by transwell migration assay. Abbreviations: CDDP, cisplatin; DMSO, dimethyl sulfoxide.
S8061	Sabutoclax Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.	Cancer Res, 2018, 78(4):1097-1109 Cancer Lett, 2018, 423:47-59 Cell Death Differ, 2016, 23(10):1681-90	(e) Abs (490 nm) was measured by MTS assay in siControl or siPTBP1 treated PC3 cells with DMSO, 1000 nM ABT737, or 100 nM Sabutoclax for 48 h, showing no significant change in cell viability following siPTBP1 treatment in DMSO control, ABT737, or Sabutoclax treated cells. (f) PC3 cells transfected with siControl or a mixture of two siPTBP1 were treated with 1000 nM ABT737 or 100 nM Sabutoclax combined with various doses of docetaxel for 48 h and cell viability was assessed by MTS assay. The viability of cells with 1000 nM ABT737 or 100 nM Sabutoclax alone was set as 100%. All data are presented as mean±S.E.M., n=3. The statistical significance was determined by unpaired student t-test where P<0.05; P<0.01; **P<0.001.
S7790	A-1210477 A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.	Cancer Cell, 2019, 35(5):752-766 Blood Cancer J, 2019, 9(2):4 Oncogene, 2019, 38(1):47-59	U251 glioblastoma (F) or MeWo melanoma (G) cells were treated with selective BH-3 mimetics, GTPP or the combination of both for 24 h (U251) or 48 h (MeWo). Thereafter, cells were stained with annexin V and propidium iodide and analyzed by flow cytometry. Shown are representative flow plots.
S2448	Gambogic Acid Gambogic Acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-X_L, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 μM, respectively.
S8383	S63845 S63845 is a new, selective MCL-1 inhibitor with the Kd value of 0.19 nM and has no discernible binding to the other BCL-2 members, BCL-2 or BCL-XL.	Cell, 2019, 178(2):302-315.e23 Nat Commun, 2019, 10(1):1444 Cell Rep, 2019, 27(12):3657-3671
S8177	BH3I-1 BH3I-1 is a Bcl-X_L-BH3 domain interaction inhibitor with Ki of 2.4 μM (by fluorescence polarization ).It is a selective inhibitor of Bcl-2 family proteins.
S7800	A-1155463 A-1155463, a highly potent and selective BCL-XL inhibitor, shows picomolar binding affinity to BCL-XL, and >1000-fold weaker binding to BCL-2 and related proteins BCL-W(Ki=19 nM) and MCL-1(Ki>440 nM).	Haematologica, 2018, 10.3324/haematol.2018.204958 Oncogenesis, 2018, 7(9):74	Tumor growth rate (TGR) of tumors orthotopically implanted in rats on day 3, 7 and 10 compared to day 0. Rats were treated with doxorubicin, A-1155463 or a combination. Treatment with A-1155463 resulted in a significant decrease in TGR compared to control mice.
S7801	A-1331852 A-1331852 is a potent and selectiveBCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.	Cancer Cell, 2019, 35(5):752-766 Cell Death Dis, 2019, 10(7):521 Cell Death Dis, 2019, 10(5):342	Cells were treated with 0.5 μM A-1331852 and 1.5 nM VCR (RD), 0.5 nM VCR (RH30) for 72 h. Apoptosis was determined by analysis of DNA fragmentation of PI-stained nuclei using flow cytometry. Mean and SD of three independent experiments performed in triplicate are shown; **P < 0.01.
S7531	UMI-77 UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.	Cell Death Dis, 2019, 10(3):185 BMC Cancer, 2017, 17(1):449 Mol Cell Biochem, 2017, 10.1007/s11010-017-2997-x	U87 and A172 cells were treated with UMI-77 (8 μM) for 24h and further treated with TRAIL (30 ng/ml) for indicated period of time. Levels of apoptosis-associated proteins were analyzed by Western blot. GAPDH was used as a loading control.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S7105	BAM7 BAM 7 is a direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

製品コード

製品説明

文献中Selleckの製品使用例

お客様のフィードバック

S7105

BAM7

BAM 7 is a direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1057	Obatoclax Mesylate (GX15-070) Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.	Cancer Cell, 2019, 36(1):68-83 Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011 Prostate, 2019, 79(11):1347-1359	In vivo antitumor efﬁcacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.
S7849	BDA-366 BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity.
S7126	Marinopyrrole A (Maritoclax) Marinopyrrole A (Maritoclax) is a selective Mcl-1 antagonist. It binds to Mcl-1, but not Bcl-XL, and targets Mcl-1 for proteasomal degradation. Maritoclax disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM.	Leukemia, 2019, 33(2):319-332

製品コード

製品説明

文献中Selleckの製品使用例

お客様のフィードバック

S1057

Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cancer Cell, 2019, 36(1):68-83

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

Prostate, 2019, 79(11):1347-1359

S7849

BDA-366

BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity.

S7126

Marinopyrrole A (Maritoclax) is a selective Mcl-1 antagonist. It binds to Mcl-1, but not Bcl-XL, and targets Mcl-1 for proteasomal degradation. Maritoclax disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM.

Leukemia, 2019, 33(2):319-332

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S8865^新	BAI1
S8650	BTSA1 BTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.

製品コード

製品説明

文献中Selleckの製品使用例

お客様のフィードバック

S8865^新

BAI1

S8650

BTSA1

BTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.

研究分野別

製品類型

Bcl-2

シグナル伝達経路

研究分野

阻害剤の選択性比較

亜型選択性的な製品

Bcl-2製品